September 15, 2023 by admin aurigene Targeting DDR1 Kinase to Address Tumor Dissemination, Immune Exclusion, and Therapeutic Resistance Aurigene’s AUR109_DDR1-SIK2-Wnt-Catenin inhibitor for PFI2023 v2
August 8, 2023 by admin aurigene Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax
July 31, 2023 by admin aurigene A phase 1, open label, dose escalation, First-in-Human (FIH) study evaluating the safety, pharmacokinetics, pharmacodynamics and efficacy of AUR 103 in patients with relapsed advanced malignancies (BHARAT-1)
May 22, 2023 by admin aurigene Generation of profound anti-tumor immunity by AUR109, a spectrum-selective kinase inhibitor, either as a single agent or in combination with immune checkpoint inhibitors 20230418_AUR109_AACR2023_4030
May 22, 2023 by admin aurigene ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces Antitumor Immunity.
May 22, 2023 by admin aurigene A highly differentiated PDL1-A2AR dual inhibitor for potential use in cancer therapy
May 2, 2023 by admin aurigene Targeting CBP/p300 – Inhibition vs Degradation for Potent Anti-tumor Efficacy
May 2, 2023 by admin aurigene Amino Acid inspired oral immune checkpoint antagonists for cancer therapy
May 1, 2023 by admin aurigene Oral Immune Checkpoint Antagonist Dually Targeting TIGIT & PD-1 Pathways for Cancer Therapy
May 1, 2023 by admin aurigene Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor
